Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

OrbusNeich's Sapphire catheter:

This article was originally published in Clinica

  • News

Executive Summary

Hong Kong firm OrbusNeich has CE marked its Sapphire 1.25mm percutaneous transluminal coronary angioplasty (PTCA) dilatation catheter for sale in Europe. The small-diameter balloon catheter is designed for pre-dilatation of tight, calcified chronic total occlusion (CTO) lesions. It provides what OrbusNeich calls "enhanced pushability and superior kink resistance". The Sapphire 1.25mm is available in 5mm, 8mm, 10mm and 15mm lengths.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

MHRA Sets Out Summer Schedule Of Medtech Regulatory Milestones

Apple Watch Feature Qualified As FDA Device Development Tool

Expert Proposes AI Device Reimbursement Model ‘Like Netflix’

Robotic-Assisted Treatment For Enlarged Prostate Shows Promising Results

See All
UsernamePublicRestriction

Register

MT046699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By